Angeles Investment Advisors LLC Has $243,000 Stake in Danaher Co. (NYSE:DHR)

Angeles Investment Advisors LLC lowered its stake in shares of Danaher Co. (NYSE:DHR) by 8.5% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,060 shares of the conglomerate’s stock after selling 98 shares during the period. Angeles Investment Advisors LLC’s holdings in Danaher were worth $243,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Heck Capital Advisors LLC bought a new stake in shares of Danaher in the 4th quarter worth approximately $27,000. Decker Retirement Planning Inc. bought a new position in Danaher in the fourth quarter worth $31,000. Golden State Wealth Management LLC acquired a new stake in Danaher during the fourth quarter worth $31,000. Strategic Financial Concepts LLC bought a new stake in Danaher in the 4th quarter valued at $31,000. Finally, Pineridge Advisors LLC raised its stake in shares of Danaher by 63.3% in the 4th quarter. Pineridge Advisors LLC now owns 147 shares of the conglomerate’s stock valued at $34,000 after buying an additional 57 shares in the last quarter. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.7 %

NYSE:DHR opened at $211.63 on Monday. The stock’s fifty day moving average price is $217.46 and its two-hundred day moving average price is $238.50. The company has a market cap of $151.26 billion, a price-to-earnings ratio of 40.08, a P/E/G ratio of 2.66 and a beta of 0.82. Danaher Co. has a 52-week low of $196.80 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.40.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $2.14. Danaher had a return on equity of 10.82% and a net margin of 16.33%. During the same period in the previous year, the business earned $2.09 EPS. On average, analysts anticipate that Danaher Co. will post 7.63 EPS for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a dividend of $0.32 per share. This is a boost from Danaher’s previous quarterly dividend of $0.27. The ex-dividend date of this dividend is Friday, March 28th. This represents a $1.28 annualized dividend and a dividend yield of 0.60%. Danaher’s payout ratio is currently 24.24%.

Insider Buying and Selling

In related news, SVP Brian W. Ellis sold 5,700 shares of Danaher stock in a transaction on Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares of the company’s stock, valued at $4,534,149.90. The trade was a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 11.10% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. Royal Bank of Canada reissued an “outperform” rating and issued a $277.00 target price (down previously from $299.00) on shares of Danaher in a research note on Thursday, January 30th. Robert W. Baird lowered their price objective on Danaher from $277.00 to $268.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. StockNews.com downgraded Danaher from a “buy” rating to a “hold” rating in a research report on Saturday, December 14th. Barclays lowered their price target on Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 30th. Finally, JPMorgan Chase & Co. reduced their target price on shares of Danaher from $310.00 to $300.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 28th. Five research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $278.24.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.